These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12504264)

  • 21. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
    Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
    J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic polypharmacy in a regional health service: a population-based study.
    Bernardo M; Coma A; Ibáñez C; Zara C; Bari JM; Serrano-Blanco A
    BMC Psychiatry; 2012 May; 12():42. PubMed ID: 22587453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic drug prescribing in the elderly is cause for concern.
    Percudani M; Barbui C; Fortino I; Petrovich L
    Int Clin Psychopharmacol; 2004 Nov; 19(6):347-50. PubMed ID: 15486521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
    McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
    J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of novel antipsychotics on glucose and lipid levels.
    Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
    J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S; Assion HJ; Stargardt T; Busse R; Juckel G; Gericke CA
    Pharmacopsychiatry; 2009 Mar; 42(2):66-71. PubMed ID: 19308881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.
    Cáceres MC; Peñas-Lledó EM; de la Rubia A; Llerena A
    Eur J Clin Pharmacol; 2008 Jan; 64(1):73-6. PubMed ID: 17952424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Zedkova I; Dudova I; Urbanek T; Hrdlicka M
    Neuro Endocrinol Lett; 2011; 32(5):667-70. PubMed ID: 22167144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns and costs of antipsychotic drug use in Taiwan: 1997 to 2001.
    Chou LF
    Adv Ther; 2003; 20(6):344-51. PubMed ID: 15058752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.